Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FORTITUDE-3: AOC 1020 in Facioscapulohumeral Muscular Dystrophy
jRCT2031250486Phase 3Recruiting
- Sponsor
- Avidity Biosciences
- Start
- Feb 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
Phase 3, randomised, double-blind trial in facioscapulohumeral muscular dystrophy (FSHD) comparing AOC 1020 2 mg/kg with Placebo (2 arms). Primary endpoint: Quantitative Muscle Testing (QMT) composite score. Started Feb 2026; status: recruiting.
02
Drugs
delpacibart braxlosiran
03
Conditions
facioscapulohumeral muscular dystrophy (FSHD)
Beyond the preview
Go deeper on jRCT2031250486.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250486.